BENGALURU (Reuters) – Aurobindo Pharma Ltd wants to discontinue the late-stage trial of Merck & Co’s experimental antiviral drug molnupiravir in moderate COVID-19 patients, the Indian drug regulator’s expert committee said on Friday.
(Reporting by Shivani Singh in Bengaluru; Editing by Rashmi Aich)
